12 Most Undervalued Dow Stocks to Buy According to Analysts

Page 8 of 10

3. Amgen Inc.  (NASDAQ:AMGN)

Price Target Upside: 20.08% 

PE Ratio: 22.26 

Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company specializing in innovative therapeutics for complex cancers and serious illnesses, is strengthening its U.S. manufacturing footprint with a major $650 million expansion announced in September 2025. The project will upgrade the biologics facility in Juncos, Puerto Rico, incorporating advanced technologies to enhance production efficiency and operational resilience. The expansion is expected to create nearly 750 new jobs, spanning construction and skilled manufacturing roles, while aligning with President Trump’s recent 100% tariffs on imported pharmaceuticals. AMGN’s domestic investment shields it from these tariffs and bolsters supply chain security.

This initiative follows earlier investments of $900 million in Ohio and $1 billion in North Carolina, reflecting Amgen Inc. (NASDAQ:AMGN)’s continued focus on scaling production to support its growing product pipeline. These strategic moves position the company to meet rising demand while maintaining operational flexibility across key U.S. sites.

Financially, the firm reported strong Q2 2025 results, with revenues rising 9% year-over-year to $9.2 billion and GAAP earnings per share surging 92%. Despite a modest recent pullback in stock price amid broader market trends, analysts maintain a positive outlook, with some viewing Amgen Inc. (NASDAQ:AMGN) as one of the most undervalued stocks in the biotech sector.

Page 8 of 10